Inhalation Sciences gets large order from AstraZeneca
STOCKHOLM, SVERIGE – 27 september, 2017. Inhalation Sciences (ISAB) has received an order for a complete PreciseInhale system, including all its test modules, from AstraZeneca.
ISAB, which recently carried out an oversubscribed share issue ahead of its listing on AktieTorget in Stockholm, develops and sells advanced lab equipment for inhalation R&D that measures how particles in inhaled air affect our health. ISAB has successfully delivered PreciseInhale to a number of other key customers and Key Opinion Leaders, including Chiesi Farmaceutici, Kings College and Dow Chemicals.
AstraZeneca has ordered PreciseInhale and the whole range of its test modules corresponding to an order value of 3.2 MSEK. The system will be delivered in stages, with the order including advanced modules still being refined and developed.
ISAB CEO Fredrik Sjövall: "This is obviously a breakthrough order for us, and we’re delighted to deepen our cooperation with AstraZeneca. We’re still just seeing the beginning of what PreciseInhale can contribute to the pharmaceutical industry. I’m convinced this will grow interest in our products worldwide”
For more information about Inhalation Sciences please contact: Fredrik Sjövall, CEO Email: email@example.com Phone: +46 (0)70 64 508 75Press release in PDF format